Dr. Rahul Aggarwal presents emerging treatments for advanced prostate cancer, highlighting rapid advances in drug development. He outlines therapies targeting cancer cell surface proteins beyond PSMA, including CD46, B7-H3, and DLL3, and explains how antibody-drug conjugates deliver potent chemotherapy directly to tumors. He also discusses bispecific T-cell engagers designed to trigger immune attacks on cancer cells, including promising results from agents like Talquetamab. Aggarwal explores new isotopes such as actinium-225 for radioligand therapy, which may offer stronger and more durable responses than current treatments. He emphasizes continued innovation in targeting the androgen receptor, with drugs that degrade the receptor or block androgen production more effectively than existing therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40813]

Ver todos los episodios